Efficacy of acemannan in treatment of canine and feline spontaneous neoplasms.
Forty-three dogs and cats with spontaneous tumors were treated with the immunostimulating polysaccharide acemannan by intraperitoneal and intralesional routes of administration. Tumors from 26 of these animals showed histopathological evidence of immunological attack as shown by marked necrosis or lymphocytic infiltration. Thirteen showed moderate to marked tumor necrosis or liquefaction. Twenty-one demonstrated lymphoid infiltration, and seven demonstrated encapsulation. Twelve animals showed obvious clinical improvement as assessed by tumor shrinkage, tumor necrosis, or prolonged survival; these included five of seven animals with fibrosarcomas. It is believed that acemannan exerts its antitumor activity through macrophage activation and the release of tumor necrosis factor, interleukin-1, and interferon.
Harris
C
C
Animal Diagnostic Clinic, Dallas, Texas.
Pierce
K
K
King
G
G
Yates
K M
KM
Hall
J
J
Tizard
I
I
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D002371:Cat Diseases / Q000188:drug therapy*; D002415:Cats; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D008297:Male; D008351:Mannans / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy / Q000662:veterinary*; D010936:Plant Extracts / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D008351:Mannans; D010936:Plant Extracts; C058414:acemannan